GT
BMRN icon

Greenleaf Trust’s BioMarin Pharmaceuticals BMRN Stock Holding History

Greenleaf Trust’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,934
Closed -$207K – 803
2025
Q1 		$207K Buy
+2,934
New +$197K ﹤0.01% 764
2024
Q4 		– Sell
-3,099
Closed -$218K – 812
2024
Q3 		$218K Buy
3,099
+36
+1% +$3.01K ﹤0.01% 774
2024
Q2 		$252K Buy
+3,063
New +$255K ﹤0.01% 670

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Greenleaf Trust's BMRN Position: Q2 2025 in Review

Greenleaf Trust sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 2,934 shares — an estimated $207K sold.

Greenleaf Trust first reported a position in BMRN in Q2 2024 and held it in 3 quarters. The position peaked at $252K in Q2 2024. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Greenleaf Trust reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Greenleaf Trust sold 2,934 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $207K.
  • Greenleaf Trust first reported a position in BioMarin Pharmaceuticals in Q2 2024 and held it in 3 quarters.
  • Greenleaf Trust's BioMarin Pharmaceuticals position peaked at $252K in Q2 2024.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Greenleaf Trust's 13F filing for Q2 2025, filed 17 Jul 2025.